COVID-19 VACCINE CANDIDATES

HOW SANOFI'S CLINICAL TRIALS WORK

During clinical trials, researchers measure the vaccine candidate's **immunogenicity, tolerability, efficacy** and monitor its safety in comparison to the effects of placebo: one group of volunteers receives the vaccine candidate and a second control group receives an inactive substance.

PHASE 1/2 CLINICAL TRIALS

Scientists seek to demonstrate that:

- the vaccine candidate stimulates an **immune response** through analysis of blood samples
- the vaccine candidate is **well-tolerated**

~500 PEOPLE
1 COUNTRY (US)



PHASE 3 CLINICAL TRIALS

Scientists seek to demonstrate that:

- the vaccine candidate meets its **efficacy objectives**, in line with those endorsed by regulators
- the vaccine candidate shows **no significant safety or tolerability issues**

~30,000 PEOPLE
SEVERAL COUNTRIES



How do we recruit volunteers and measure the results of clinical trials?

Before the trial starts, health authorities approve its design and monitor the trial throughout the whole process.

Research networks (hospitals, universities) recruit volunteers and monitor their health status. Volunteers are people over the age of 18 and include high-risk groups such as the elderly and those with chronic diseases.

Volunteers are vaccinated, then tested after a set number of days at a clinical center.

Sanofi and independent expert scientists analyze health data from all volunteers and pause the trial if any safety question arises.

IF RESEARCHERS CAN DEMONSTRATE THE VACCINE'S EFFICACY AND GOOD SAFETY PROFILE, THE VACCINE IS **READY FOR FINAL ASSESSMENT TO HEALTH AUTHORITIES FOR THEIR APPROVAL.**

SANOFI PASTEUR

MAT-GLB-2003075 V2.0 - 10/2020